Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: UTI - Lower Urinary Tract Infection Clear all

Conditions: UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Urinary Tract Infections
Interventions: LBP-EC01, Placebo; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Anniston, Alabama • Irvine, California • Doral, Florida + 4 more

Conditions: Urinary Tract Infection, Leiomyoma
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 860 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions: D-Mannose, Placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neurogenic Bladder, Non-Neurogenic Bladder
Interventions: Not listed
Lead sponsor: Hollister Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Libertyville, Illinois

Conditions: Urinary Tract Infections
Interventions: Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture; Diagnostic Test
Lead sponsor: Pathnostics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Barrington, Illinois

Conditions: Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions: Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stress Incontinence
Interventions: Nitrofurantoin, Placebo; Drug · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions: Health Information Prescription; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Infections, Urinary Tract
Interventions: GSK2251052, imipenem-cilastatin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more

Conditions: Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions: Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg); Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Pelvic Organ Prolapse, Urinary Incontinence, Pelvic Floor Disorders, Gynecologic Disease, Post-Op Infection, Surgical Site Infection, Urinary Tract Infections
Interventions: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions: Gentamicin, Lactobacillus Rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: Lower Urinary Tract Symptoms, Lower Urinary Tract Infection
Interventions: Midstream urine collection device, Catheter for urine collection; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Overactive Bladder
Interventions: Solifenacin; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions: Extended Urine Culture; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Urinary Tract Infections, Urinary Retention, Satisfaction
Interventions: Fast Track foley removal; Other
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions: Replens and coconut oil; Combination Product
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Overactive Bladder, Urinary Tract Infection
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Postoperative Urinary Tract Infection, Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions: gentamicin sulfate, Catheter clamping only; Drug · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Urinary Tract Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 31
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 25 more

Conditions: Stress Urinary Incontinence
Interventions: Bactrim or Macrobid, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Antibiotic Stewardship, Overactive Bladder, Onabotulinumtoxin A, UTI
Interventions: No antibiotic, Prophylactic antibiotic, cystoscopic injection of onabotulinumtoxinA; Other · Procedure
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Voiding Dysfunction
Interventions: Control Group, Test Group; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

Continence Care Registry

Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

GSK2251052 in Complicated Urinary Tract Infection

Prophylactic Antibiotics for Outpatient Urethral Bulking

Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

PEEZY Midstream Urine Device Compared to Catheterized Urine Sample

Bacterial Genomic Sequencing in Overactive Bladder

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

Urinary Cytokines in Patients With Overactive Bladder (OAB)

Gentamicin Intravesical Efficacy for Infection of Urinary Tract

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery